RxDoctor Payments Data

Cristina Aseron, MD

Critical Care Medicine · Mansfield, TXNPI 1811070436

Payments from drug & device makers

$2,008in general payments, 2019–2025

Across 127 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$213
  • Johnson & Johnson$198
  • Lilly USA, LLC$194
  • Novo Nordisk$153
  • Novartis$135
  • Pfizer$129
  • plus $986 from 21 others

What the payments were for

  • Food & beverage$2,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,008 in reported general payments places this provider in the 70th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$7,917
Medicare patients
48
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$38,738
OzempicSemaglutide22$25,279
TrulicityDulaglutide17$24,210
XareltoRivaroxaban20$22,418
JanuviaSitagliptin Phosphate24$19,641
VascepaIcosapent Ethyl16$13,194
LinzessLinaclotide13$12,246
Tresiba Flextouch U-200Insulin Degludec17$12,079
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$7,519
JanumetSitagliptin Phos/Metformin Hcl11$7,217
PremarinEstrogens, Conjugated12$3,787
Omeprazole100$2,533
Gabapentin107$2,414
Levothyroxine Sodium187$2,163
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$129$42,52554 claims
MerckJanuvia, Janumet$45$26,85835 claims
Novo NordiskOzempic$153$25,27922 claims
Lilly USA, LLCTrulicity$194$24,21017 claims
Johnson & JohnsonXarelto$198$22,41820 claims
AbbVieLinzess$71$12,24613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →